IBL-301 inhibited activation of several proliferative pathways including the MAP kinase pathway proteins ERK and p38, PI3K-Akt pathway and JAK/STAT pathway in NSCLC tumor explants. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.